Global Blood Product Market Growth (Status and Outlook) 2025-2031

The global Blood Product market size is predicted to grow from US$ 34560 million in 2025 to US$ 54170 million in 2031; it is expected to grow at a CAGR of 7.8% from 2025 to 2031.

Blood Products are medical products derived from human blood and used for the treatment of various conditions. They include whole blood, blood components like red blood cells, platelets, and plasma, as well as plasma derivatives such as clotting factors and immunoglobulins. Blood products are essential in medical treatments, including surgeries, trauma care, and for patients with blood disorders, anemia, or immune deficiencies.

Market Drivers:

Increasing Demand for Plasma-Derived Therapies: The rising prevalence of chronic diseases, such as immune deficiencies, hemophilia, and autoimmune disorders, has led to increased demand for plasma-derived products like immunoglobulins, clotting factors, and albumin, driving the Plasma Fractionation Technology market.

Aging Population: The global aging population is more prone to chronic diseases and conditions requiring plasma-derived therapies, contributing to the growth of the Plasma Fractionation Technologyation market.

Growing Use of Immunoglobulins: Immunoglobulins are increasingly used in the treatment of a wide range of diseases, including primary and secondary immune deficiencies, boosting the need for Plasma Fractionation Technology to produce these therapies.

Rising Healthcare Expenditure and Improved Healthcare Access: Expanding healthcare infrastructure in developing countries, combined with rising healthcare expenditure, is driving demand for advanced medical treatments and plasma-derived products.

Market Challenges:

High Costs of Plasma-Derived Products: The complex and time-consuming process of Plasma Fractionation Technologyation leads to high costs for plasma-derived products, making these treatments less accessible, particularly in low-income regions.

Limited Plasma Supply: The availability of plasma for fractionation is often limited by low donation rates, regulatory restrictions, and the lengthy process of screening and collecting plasma, leading to supply shortages.

Stringent Regulatory Framework: Plasma Fractionation Technologyation is subject to rigorous regulatory requirements to ensure safety and efficacy. Meeting these regulations can increase development costs and slow the introduction of new products to the market.

Complex Manufacturing Process: The Plasma Fractionation Technologyation process is technically challenging and requires significant investment in infrastructure, equipment, and skilled labor, posing barriers for new entrants and smaller manufacturers.

The outbreak of COVID-19 pandemic has led to decrease in number of blood donations and plasma collections, which hampers the market growth as it leads to shortage in raw material supply.

The classification of Plasma Fractionation Technology includes Immune Globulin, Coagulation Factor, Albumin and Other. In 2023, Immune Globulin accounted for a share of 51% in the global Plasma Fractionation Technology market.

North America is the largest consumption place, with a revenue market share nearly 40% in 2023. Following North America, Europe is the second largest consumption place with the revenue market share of 24 %; China is also an important sales region for the Plasma Fractionation Technology.

LPI (LP Information)' newest research report, the “Blood Product Industry Forecast” looks at past sales and reviews total world Blood Product sales in 2024, providing a comprehensive analysis by region and market sector of projected Blood Product sales for 2025 through 2031. With Blood Product sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Blood Product industry.

This Insight Report provides a comprehensive analysis of the global Blood Product landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Blood Product portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Blood Product market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Blood Product and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Blood Product.

This report presents a comprehensive overview, market shares, and growth opportunities of Blood Product market by product type, application, key players and key regions and countries.

Segmentation by Type:
Albumin
Immunoglobulin
Clotting Factor
Others

Segmentation by Application:
Hospital
Retail Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics

Please note: The report will take approximately 2 business days to prepare and deliver.